149 related articles for article (PubMed ID: 18091608)
1. Enfuvirtide does not require dose adjustment in patients with chronic kidney failure: results of a pharmacokinetic study of enfuvirtide in HIV-1-infected patients with impaired kidney function.
Tebas P; Bellos N; Lucasti C; Richmond G; Godofsky E; Patel I; Chiu YY; Evans C; Rowell L; Salgo M
J Acquir Immune Defic Syndr; 2008 Mar; 47(3):342-5. PubMed ID: 18091608
[TBL] [Abstract][Full Text] [Related]
2. Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients.
Ruxrungtham K; Boyd M; Bellibas SE; Zhang X; Dorr A; Kolis S; Kinchelow T; Buss N; Patel IH
J Clin Pharmacol; 2004 Jul; 44(7):793-803. PubMed ID: 15199084
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects.
Thompson M; DeJesus E; Richmond G; Wheeler D; Flaherty J; Piliero P; True A; Chiu YY; Zhang Y; McFalls E; Miralles GD; Patel IH
AIDS; 2006 Feb; 20(3):397-404. PubMed ID: 16439873
[TBL] [Abstract][Full Text] [Related]
4. Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide.
Boyd MA; Zhang X; Dorr A; Ruxrungtham K; Kolis S; Nieforth K; Kinchelow T; Buss N; Patel IH
J Clin Pharmacol; 2003 Dec; 43(12):1382-91. PubMed ID: 14615475
[TBL] [Abstract][Full Text] [Related]
5. Mechanism-based model of the pharmacokinetics of enfuvirtide, an HIV fusion inhibitor.
Mohanty U; Dixit NM
J Theor Biol; 2008 Apr; 251(3):541-51. PubMed ID: 18258267
[TBL] [Abstract][Full Text] [Related]
6. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
Lalezari JP; DeJesus E; Northfelt DW; Richmond G; Wolfe P; Haubrich R; Henry D; Powderly W; Becker S; Thompson M; Valentine F; Wright D; Carlson M; Riddler S; Haas FF; DeMasi R; Sista PR; Salgo M; Delehanty J
Antivir Ther; 2003 Aug; 8(4):279-87. PubMed ID: 14518696
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy.
Bellibas SE; Siddique Z; Dorr A; Bertasso A; Sista P; Kolis SJ; Cotler S; Delora P;
Pediatr Infect Dis J; 2004 Dec; 23(12):1137-41. PubMed ID: 15626952
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic bioequivalence of enfuvirtide using a needle-free device versus standard needle administration.
True AL; Chiu YY; Demasi RA; Stout R; Patel I
Pharmacotherapy; 2006 Dec; 26(12):1679-86. PubMed ID: 17125431
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients.
de Requena DG; Bonora S; Castagna A; Hasson H; Marucco DA; D'Avolio A; Sciandra M; Trentini L; Calcagno A; Lazzarin A; Di Perri G
J Antimicrob Chemother; 2008 Aug; 62(2):384-7. PubMed ID: 18487231
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of enfuvirtide in HIV-1-infected pediatric patients over 48 weeks of treatment.
Zhang X; Lin T; Bertasso A; Evans C; Dorr A; Kolis SJ; Salgo M; Patel I;
J Clin Pharmacol; 2007 Apr; 47(4):510-7. PubMed ID: 17389560
[TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients.
Wheeler DA; Lalezari JP; Kilby JM; Wheat J; Delehanty J; DeMasi R; Patel I; Salgo M
J Clin Virol; 2004 Jun; 30(2):183-90. PubMed ID: 15125875
[TBL] [Abstract][Full Text] [Related]
12. [Enfuvirtide, first fusion inhibitor in the treatment of human immunodeficiency virus infection: mechanism of action and pharmacokinetics].
Raffi F
Med Mal Infect; 2004 Sep; 34 Spec No 1():3-7. PubMed ID: 15742549
[TBL] [Abstract][Full Text] [Related]
13. Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin.
Price RW; Parham R; Kroll JL; Wring SA; Baker B; Sailstad J; Hoh R; Liegler T; Spudich S; Kuritzkes DR; Deeks SG
Antivir Ther; 2008; 13(3):369-74. PubMed ID: 18572749
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients.
Mould DR; Zhang X; Nieforth K; Salgo M; Buss N; Patel IH
Clin Pharmacol Ther; 2005 Jun; 77(6):515-28. PubMed ID: 15961983
[TBL] [Abstract][Full Text] [Related]
15. Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients.
Lalezari JP; Patel IH; Zhang X; Dorr A; Hawker N; Siddique Z; Kolis SJ; Kinchelow T
J Clin Virol; 2003 Oct; 28(2):217-22. PubMed ID: 12957192
[TBL] [Abstract][Full Text] [Related]
16. Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector).
Harris M; Joy R; Larsen G; Valyi M; Walker E; Frick LW; Palmatier RM; Wring SA; Montaner JS
AIDS; 2006 Mar; 20(5):719-23. PubMed ID: 16514302
[TBL] [Abstract][Full Text] [Related]
17. Enfuvirtide, a new drug for HIV infection.
Fletcher CV
Lancet; 2003 May; 361(9369):1577-8. PubMed ID: 12747873
[No Abstract] [Full Text] [Related]
18. Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection.
Hardy H; Skolnik PR
Pharmacotherapy; 2004 Feb; 24(2):198-211. PubMed ID: 14998221
[TBL] [Abstract][Full Text] [Related]
19. [Enfuvirtide: first drug of a new family of antiretroviral agents].
Espona M; Ferrández O; Grau S; Carmona A
Farm Hosp; 2005; 29(6):375-83. PubMed ID: 16433570
[TBL] [Abstract][Full Text] [Related]
20. Enfuvirtide: a fusion inhibitor for the treatment of HIV infection.
Fung HB; Guo Y
Clin Ther; 2004 Mar; 26(3):352-78. PubMed ID: 15110129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
